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Abstract: Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people
and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide.
Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease
inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of
hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and
is an all-oral once daily treatment option for HCV infection. Efficacy of grazoprevir/elbasvir
has been proven in patients with cirrhosis, patients who have previously failed treatment with
peginterferon and ribavirin (RBV), patients with end-stage renal disease and patients with HIV
co-infection. Data have shown a high barrier to resistance despite the presence of resistanceassociated substitutions. Grazoprevir/elbasvir represents a very promising regimen for treatment
of HCV infection. This review provides a summary of pharmacology, efficacy, and safety of
grazoprevir/elbasvir for the treatment of HCV infection.
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Introduction
For more than 25 years, pegylated interferon and ribavirin (PR) have been the mainstay
of treatment for hepatitis C virus (HCV) infection until the recent advent of protease
inhibitors.1–3 The emergence of protease inhibitor therapies in 2011 transformed the
landscape of HCV treatment. However, there have been major limitations with initial
direct-acting antiviral (DAA) agents including low genetic barrier to resistance, side
effects, and significant drug-drug interactions.4–6
Grazoprevir is a second-generation NS3/4a protease inhibitor that demonstrates
activity against resistance-associated substitutions (RAS) seen after failed therapy
with first-generation protease inhibitors.7–12 Elbasvir is a NS5A replication complex
inhibitor. Grazoprevir-Elbasvir has been approved by Food and Drug Administration
(FDA) since 2016 for the treatment of HCV genotype 1 and 4 and with ribavirin in
select patient populations. It has also been studied in patients with advanced chronic
kidney disease (CKD). The purpose of this review is to summarize pharmacology,
efficacy, and safety of grazoprevir-elbasvir.
Correspondence: Nimisha Sulejmani
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Pharmacology
Grazoprevir is a synthetically derived quinoline-based p2-p4 macrocyclic derivative
that is a strong inhibitor of HCV NS3/4A protease.13 NS3/4A protease is responsible
for cleaving the long polyprotein produced from hepatitis C viral RNA template into
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single proteins. This is an essential process for HCV RNA
replication, which is inhibited by grazoprevir. The HCV
NS5A is a critical RNA binding protein associated with performing necessary functions for viral replication and virion
assembly. Elbasvir directly inhibits the activity of NS5A
protein within the HCV.

Pharmacokinetics and metabolism
Initial studies to evaluate pharmacokinetics of grazoprevir
were performed in rats, dogs, and simian models.14–16 Oral (5
mg/kg of body weight in rats and 1 mg/kg of body weight in
dogs) and intravenous (bolus dose of 2 mg/kg of body weight
in rats and 0.5 mg/kg of body weight in dogs) formulations
were utilized in the studies.
The safety and pharmacokinetics of grazoprevir were
evaluated by Brainard et al in healthy males after single-dose
and multiple-dose administration.17 An oral dose of 2–1,600
mg or placebo in fed or fasted state was administered to
24 healthy males in the single dose group. An oral dose of
100–1,000 mg or placebo once daily for 10 days was administered in 40 healthy males in the multiple-dose group. No
serious adverse events occurred in the study, with one subject
experiencing flu-like illness unrelated to the drug. Following
single administration of an oral dose, the pharmacokinetic
data revealed Tmax values of 2–5 hours and a terminal halflife of 15–34.4 hours. Pharmacokinetics was not affected by
administration of the medication with a high-fat meal. Dose
proportional increases in mean area under the curve (AUC),
Cmax, and 24 hour concentration values were seen up to 200
mg. These values were much higher and did not increase
in a dose proportional manner in doses greater than 200 mg.
Steady state was obtained after six doses, and approximately
three-fold increase in AUC and Cmax was noted for grazoprevir doses of 100–400 mg. Only 1.5-fold increase in AUC
and Cmax was observed at doses higher than 400 mg.
Mean AUC and Cmax increased in a greater than dose
proportional manner at steady state in the multiple-dose group
with median Tmax of 2.5–4 hours and half-life of 20 hours.
The single-dose and multiple-dose groups demonstrated
consistent pharmacokinetic data. Pharmacokinetic data were
evaluated in six patients with HCV in another study, one with
genotype 1 and five with genotype 3, which yielded higher
drug exposure as compared to healthy controls (1.2–2.1 fold).18
A non-randomized, open-label Phase II study (C-SALT
trial) assessed the efficacy, safety, and pharmacokinetics of
grazoprevir plus elbasvir in patients with HCV genotype 1, 4,
or 6 infection and Child-Pugh-B (CP-B) cirrhosis.19 Pharmacokinetics of 30 patients with HCV genotype 1 infection and
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CP-B cirrhosis who received grazoprevir 50 mg and elbasvir
50 mg as separate entities was compared to that of 10 noncirrhotic patients with HCV genotype 1 who received grazoprevir 100 mg/elbasvir 50 mg combination product. Plasma
samples over 24 hours at treatment week 4 were collected in
a subset of CP-B and non-cirrhotic patients. Results of the
study demonstrated the exposure of elbasvir was similar in
both groups but grazoprevir exposure was higher in CP-B
cirrhotic patients compared to non-cirrhotic patients.

Clinical efficacy
In a randomized active-control trial, Manns et al evaluated the
safety and efficacy of PR combined with either grazoprevir
or boceprevir.20 Treatment-naïve patients with genotype 1
infection and HCV RNA level ≥104 IU/mL at screening were
eligible. The study randomized 332 treatment-naïve genotype
1 patients (60% with genotype 1a) to receive either boceprevir
+ PR at standard doses (control) or grazoprevir 100, 200, 400,
or 800 mg daily + PR for 12 weeks. Patients received an additional 12 weeks of PR alone if they achieved rapid virologic
response (RVR), defined as HCV RNA not detected at week
4 of treatment, or 36 weeks of PR if RVR was not achieved.
The study demonstrated higher sustained virologic response
(SVR) rate at the 24-week follow-up (SVR24) in the grazoprevir
group (86%–93%) compared to the boceprevir group (61%).
Howe et al further explored the study to evaluate six
patients with virologic failure.21 The substitutions associated with clinical resistance to other protease inhibitors
were present in 73 of 261 (28%) patients in the grazoprevir
group at study enrollment. SVR24 was observed in 85% of
these patients with genotype 1a and in 97% of the patients
with genotype 1b despite the presence of variants. SVR24 was
achieved in 59 of 66 patients (89%) in the 100 mg/day group.
Lagging and colleagues evaluated the efficacy of lower
doses of grazoprevir in treatment naïve HCV genotype 1
patients with HCV RNA level ≥10,000 IU/mL.22 Primary
objective was SVR rate at 12 weeks after the end of treatment (SVR12) for each group. Patients were randomized to
receive grazoprevir 25 mg (n=29), 50 mg (n=28), or 100 mg
(n=30) + PR for 12 weeks. Treatment with PR was extended
by 12 weeks if HCV RNA was detectable at week 4. Of the
87 patients enrolled, 80% were genotype 1a and 18% were
African American. SVR12 was achieved in 54.2%, 84%, and
88.5% of patients in grazoprevir 25 mg, 50 mg and 100 mg
groups, respectively. Treatment failure occurred in 46%,
16%, and 15% of patients in grazoprevir 25 mg, 50 mg, and
100 mg groups, respectively. RAS were present in 38 of 87
patients (44%) at baseline, all of which were susceptible
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to grazoprevir. Type and frequency of adverse events were
similar in all three groups.
C-WORTHY was a randomized, multi-center, open-label,
Phase II trial that evaluated safety and efficacy of 8 weeks
versus 12 weeks of treatment with grazoprevir and elbasvir
with or without ribavirin in HCV genotype 1 mono-infected
and HIV/HCV co-infected patients. 23 Treatment-naïve
patients with HCV RNA ≥10,000 IU/mL without cirrhosis
were eligible to participate. HIV co-infected patients were
required to be well controlled with raltegravir plus two
nucleoside or nucleotide reverse transcriptase inhibitors for
at least 8 weeks prior to enrollment and have undetectable
HIV RNA for at least 24 weeks with CD4 count of 300 cells/
mL or higher. Table 1 describes randomization of patients in
eight study arms. Patients’ bodyweight was utilized for ribavirin dosing (800–1,400 mg/day). The primary objective was
to assess SVR12 for each group. The majority of the patients
enrolled in the study were White (88%) males (59%) with
median age of 52 years. Baseline HCV RNA was >2,000,000
IU/mL in 56% of the patients and 72% had HCV genotype 1a
infection. In the co-infected patients, there were more males
(80%) with younger age (mean 47 years) and higher baseline
HCV RNA count. SVR12 was achieved in 93% with ribavirin
and 98% without ribavirin treatment in the mono-infected
patients treated for 12 weeks. In the co-infected patients, the
SVR12 rate was 97% with ribavirin and 87% without ribavirin. No significant differences were noted in SVR12 rates for
mono-infected and co-infected patients, for regimens with
or without ribavirin, and dose of elbasvir. The SVR12 rates
were lower in HCV genotype 1a patients receiving treatment
for 8 weeks (80%) compared to 12 weeks (95%). Virologic
failure occurred in 12 patients in the study, 10 patients with
genotype 1a and two with genotype 1b.
The C-WORTHY part B study enrolled patients with
genotype 1, treatment naïve, with cirrhosis (cohort 1) and

patients who previously failed treatment with PR, with or
without cirrhosis (cohort 2).24 Patients were randomized to
receive grazoprevir 100 mg/elbasvir 50 mg with or without
ribavirin for 12 or 18 weeks. Patients were randomized in
eight treatment groups as described in Table 2. Median age of
the patients in the study was 56 years with most having cirrhosis (67%); 58% were males, and 92% were White. Patients
in cohort 1 achieved SVR12 rates of 90%–97% with no significant benefit of extended treatment duration. One patient
in cohort 1 had virologic breakthrough and five patients had
virologic relapse. Patients in cohort 2 achieved SVR12 rates
of 91%–100%, which was similar to treatment-naïve patients
with cirrhosis. One patient had virologic breakthrough and
three patients had virologic relapse. A subgroup analysis to
assess the impact of ribavirin showed it did not contribute
to additional efficacy in patients with cirrhosis, in patients
who have previously failed PR therapy, and patients with
high viral loads (>10,000,000 IU/mL).
C-WORTHY part D study compared the efficacy of
grazoprevir 100 mg/elbasvir 50 mg with ribavirin therapy in
HCV genotype 3 patients for 12 weeks versus 18 weeks.25
This was an open-label study with patients randomized in
1:1 fashion with primary endpoint of SVR12. A total of 21
patients were included in the 12-week (W12) group and 20
patients in the 18-week (W18) group. SVR12 rate of 45% was
achieved in W12 group and 57.1% in W18 group. Breakthrough viremia occurred in six patients in W12 group and
five patients in W18 group; none of the patients experienced
relapse. There were 35 patients with baseline NS3 RAS and
18 (51%) achieved SVR12. Seven out of 17 patients (41%) in
W12 group and 11 out of 18 (61%) in W18 group achieved
SVR12. There were seven patients with baseline NS5A RAS
and three (43%) achieved SVR12. Two of five patients (40%)
in W12 group and one of two patients (50%) in W18 group
achieved SVR12.

Table 1 C-WORTHY – study treatment groups
Treatment
arm

Number of
patients*

Infection

HCV
genotype

Treatment

Duration

SVR12

1
2
3
4
5
6
7
8

25
27
13
30
33
31
29
30

Mono-infected
Mono-infected
Mono-infected
Mono-infected
Mono-infected
Mono-infected
Co-infected
Co-infected

1a + 1b
1a + 1b
1b
1a

Grazoprevir 100 mg + elbasvir 20 mg + ribavirin
Grazoprevir 100 mg + elbasvir 50 mg + ribavirin
Grazoprevir 100 mg + elbasvir 50 mg
Grazoprevir 100 mg + elbasvir 50 mg + ribavirin
Grazoprevir 100 mg + elbasvir 50 mg + ribavirin
Grazoprevir 100 mg + elbasvir 50 mg
Grazoprevir 100 mg + elbasvir 50 mg + ribavirin
Grazoprevir 100 mg + elbasvir 50 mg

12 weeks
12 weeks
12 weeks
8 weeks
12 weeks
12 weeks
12 weeks
12 weeks

93%
93%
98%
80%
93%
98%
97%
87%

1a + 1b
1a
1a + 1b
1a + 1b

Notes: *Treatment-naïve and non-cirrhotic patients. Data from Sulkowski et al.23
Abbreviations: HCV, hepatitis C virus; SVR12, sustained virologic response 12 weeks after treatment completion
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Table 2 C-WORTHY – Part B study treatment groups

Previously untreated;
with cirrhosis

PR-null, with or
without cirrhosis

Treatment
arm

Number of
patients

Treatment

Duration

SVR12

1
2
3
4
5
6
7
8

31
29
32
31
32
33
33
32

Grazoprevir 100 mg/elbasvir 50 mg + ribavirin
Grazoprevir 100 mg/elbasvir 50 mg
Grazoprevir 100 mg/elbasvir 50 mg + ribavirin
Grazoprevir 100 mg/elbasvir 50 mg
Grazoprevir 100 mg/elbasvir 50 mg + ribavirin
Grazoprevir 100 mg/elbasvir 50 mg
Grazoprevir 100 mg/elbasvir 50 mg + ribavirin
Grazoprevir 100 mg/elbasvir 50 mg

12 weeks
12 weeks
18 weeks
18 weeks
12 weeks
12 weeks
18 weeks
18 weeks

90%
97%
97%
94%
94%
91%
100%
97%

Note: Data from Lawitz et al.24
Abbreviations: SVR12, sustained virologic response 12 weeks after treatment completion; PR-null, previously untreated with Peg-interferon and Ribavirin.

C-EDGE-TN was a Phase III study that evaluated the efficacy and safety of grazoprevir/elbasvir fixed-dose combination regimen without interferon or ribavirin in treatment-naïve
patients mono-infected with HCV genotypes 1, 4, or 6 with or
without cirrhosis.26 Patients received a fixed-dose combination
of grazoprevir 100 mg/elbasvir 50 mg at the start of the study
(immediate-treatment group) or placebo (deferred treatment
group) for 16 weeks following which they received treatment
in an open-label manner. The study aimed to enroll 20% of
patients with cirrhosis and 15% with genotype 4 or genotype
6 infection. A total of 421 patients were enrolled, of whom
54% were male, 63% White, 6% with genotype 4, 3% with
genotype 6, and 91% genotype 1, and 22% of the patients
had cirrhosis. The SVR12 rates were 92% in patients with
genotype 1 infection, 100% in genotype 4 infection, and 80%
in genotype 6 infection. SVR12 rates between cirrhotic and
non-cirrhotic patients were similar; 97% vs 94% respectively.
Virologic failure was seen in 13 patients (11 with genotype 1
and two with genotype 6 infection).
The C-EDGE Co-Infection study was a Phase II study
evaluating 218 patients with hepatitis C genotype 1, 4, or 6
and HIV.27 Patients were treated with a combination therapy of
grazoprevir 100 mg/elbasvir 50 mg once daily for 12 weeks.
Patients were eligible to enroll if they were on antiretroviral
therapy for at least 8 weeks with an undetectable HIV RNA
level, and CD4 count greater than 200 cells/mm3 or HIV
treatment-naïve patients with CD4 count greater than 500
cells/mm3 and an HIV RNA level less than 50,000 copies/
mL. SVR12 was attained in 210 patients (96%) and all 35
patients with cirrhosis achieved SVR12.
C-SALVAGE was a Phase II study that evaluated the
safety and efficacy of 12 weeks of grazoprevir 100 mg/elbasvir 50 mg daily in patients with prior treatment failure with a
regimen containing a protease inhibitor such as boceprevir,
telaprevir, or simeprevir.28 The study included patients with
or without cirrhosis. SVR24 rates were high at 96.2% in
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spite of prior exposure and presence of NS3 substitutions.
Ninety two percent (33/36) of patients with baseline NS3 or
NS5A resistance and 94% (32/34) of patients with cirrhosis
achieved SVR24.
The C-SURFER was a randomized, parallel-group,
placebo-controlled study that evaluated efficacy and safety of
grazoprevir 100 mg/elbasvir 50 mg in patients with advanced
(stage 4–5) CKD infected with HCV genotype 1.29 This study
included patients who had failed pegylated interferon therapy
and treatment-naïve patients with or without cirrhosis. Of the
122 patients who received treatment in the immediate group,
80% were treatment naïve, 6% had cirrhosis, and 52% were
genotype 1a. The study comprised 18% of patients with
stage 4 and 82% of patients with stage 5 CKD, with 76% on
hemodialysis. SVR12 was 99% in the immediate group and
98% in the deferred treatment group. SVR12 was achieved
by 11 (84·6%) of 13 patients with detectable baseline NS5A
RAS and 100% of patients with genotype 1a infection.
The C-SALT trial was a non-randomized, open-label
Phase II study that assessed the efficacy, safety, and pharmacokinetics of grazoprevir plus elbasvir in patients with
HCV genotype 1, 4, or 6 infection and CP-B cirrhosis.19 The
study enrolled 30 patients with HCV genotype 1 infection
and CP-B cirrhosis who received grazoprevir 50 mg/elbasvir
50 mg and 10 non-cirrhotic patients with HCV genotype 1
who received grazoprevir 100 mg/elbasvir 50 mg in the pharmacokinetics analyses group. All patients received treatment
for 12 weeks. SVR12 was achieved in 90% of patients with
CP-B cirrhosis and in 100% of non-cirrhotic patients. Relapse
occurred in two patients in the CP-B cirrhosis arm and one
patient died due to progression of liver disease versus none in
the non-cirrhotic arm. At the 12-week follow-up, Child-Pugh
score decreased in 18 patients and increased in four patients
in the CP-B cirrhosis group.
C-EDGE CO-STAR was a Phase III study evaluating the efficacy and safety of grazoprevir and elbasvir in
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treatment-naïve, HCV genotype 1, 4, or 6 infected patients
receiving opioid agonist therapy for at least 3 months.30 This
was a double blind, placebo-controlled, parallel-group study
in which patients were randomized in a 2:1 fashion to an
immediate treatment group (ITG) or a deferred treatment
group (DTG). The ITG group received grazoprevir/elbasvir for
12 weeks and the DTG group received placebo for 12 weeks,
followed by 12 weeks of open-label grazoprevir/elbasvir.
Patients were allowed to use non-prescribed drugs, which
were monitored by urine drug screens. Of the 301 patients
randomized, 76% had genotype 1a, 15% had genotype 1b,
6% had genotype 4, 5% had genotype 6, 20% had cirrhosis,
and 7% had HIV. At baseline, 79% were receiving methadone
and 21% were receiving buprenorphine. A positive urine drug
screen was present in 59% of patients for at least one of the
following eight drug classes: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, phencyclidine,
and propoxyphene. Cocaine positivity was present in 10% of
the patients, and opiate positivity was present in 25% of the
patients. The modified data showed an SVR12 rate of 95%
overall. Five patients were successfully treated but had virologic failure with a different genotype, subtype, or viral strain.
Asselah et al evaluated 103 HCV genotype 4 infected
patients.31 They analyzed 66 treatment-naïve (TN) patients
and 37 treatment-experienced (TE) patients, including 17

cirrhotic patients. Overall, 97% of the TN (6/6 cirrhotic
patients) and 86% of the TE genotype 4 patients achieved
SVR12. Among TE patients, 9/9 prior relapsers and 23/28
prior on treatment failures achieved SVR12. Among TE cirrhotic patients, 77%, including 3/3 prior relapsers and 4/4
treated with grazoprevir/elbasvir and ribavirin for 16 weeks,
achieved SVR12. Longer duration of treatment and use of
ribavirin increased the response rate in patients with prior
on therapy failure.
Additional pertinent studies evaluating the use of grazoprevir/elbasvir therapy in various patient populations are
described in Table 3.32–35

Safety and tolerability
Various studies have demonstrated favorable safety and tolerability profile for grazoprevir. Transient and mild adverse
events were reported in an initial phase I study utilizing
grazoprevir doses from 50 mg to 800 mg daily for a week in
84 HCV genotype 1 and three non-cirrhotic patients.18 In a
randomized, active-controlled trial, Manns et al evaluated the
safety and efficacy of PR combined with either grazoprevir
or boceprevir.20 Patients received grazoprevir 100 mg, 200
mg, 400 mg, or 800 mg daily with standard dose PR, or
boceprevir with PR at standard doses. Safety was evaluated
in 332 patients and the rate of serious adverse events was

Table 3 Additional studies evaluating use of grazoprevir/elbasvir for treatment of HCV
Study

Study design

Treatment

Genotype

Patient population

SVR

Brown et al32

Randomized,
open-label, Phase II

Genotype 2: GZR 100
mg + RBV ± EBR 50 mg
for 12 weeks; genotype
4, 5 or 6: randomized to
GZR/EBR ± RBV for 12
weeks.

2, 4, 5, or 6

Treatment naïve, noncirrhotic patients

Hezode
et al33

Randomized,
placebocontrolled, Phase
III study

12 weeks of GZR/EBR
100 mg/50 mg in ITG vs
DTG

1, 4, or 6

Kwo et al34

Randomized,
open-label, Phase
III study

12 vs 16 weeks of
treatment with GZR/
EBR 100 mg/50 mg ± RBV

1,4, or 6

Sperl et al35

Randomized,
open-label, Phase
III study

12 weeks of GZR/EBR
100 mg/50 mg (n=129)
vs sofosbuvir 400 mg +
PR (n=128)

1 or 4

159 patients with
HCV and sickle cell
anemia, thalassemia,
or hemophilia A/B
or von Willebrand
disease
420 patients included:
35% with cirrhosis,
64% with null or
partial response to PR
treatment.
83% non-cirrhotic,
75% treatment naïve,
82% genotype 1b

Genotype 2: SVR12 of 80% in GZR/EBR +
RBV and 73% in GZR + RBV.
Genotype 4: SVR12 of 90% in GZR/EBR
and 100% in GZR/EBR + RBV. Genotype
5: SVR12 of 25% in GZR/EBR vs 100% in
GZR/EBR + RBV. Genotype 6: SVR12 of
75% in both groups
SVR12 of 93.5% in the ITG. SVR12 was
achieved in 94.7%, 97.6%, and 89.4%
of patients with sickle cell disease,
b-thalassemia, and hemophilia A/B or von
Willebrand disease, respectively
12 weeks of treatment: SVR12 of 92% in
GZR/EBR vs SVR12 of 94% in GZR/EBR +
RBV
16 weeks of treatment: SVR12 of 92% in
GZR/EBR vs 98% in GZR/EBR + RBV
SVR12 of 99% in GZR/EBR group and 90%
in sofosbuvir/PR group

Abbreviations: DTG, deferred treatment group; EBR, elbasvir; GZR, grazoprevir; HCV, hepatitis C virus; ITG, immediate treatment group; RBV, ribavirin; SVR12, sustained
virologic response 12 weeks after treatment completion; PR, Peg-interferon + ribavirin.
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similar in both groups (9% in grazoprevir group and 8%
boceprevir group). The rate of adverse events leading to
discontinuation of therapy was 7% in the grazoprevir group
and 14% in the boceprevir group. Transaminase levels were
increased significantly in patients receiving 400 mg and
800 mg doses of grazoprevir. The grazoprevir dose in these
patients was decreased to 100 mg and transaminase levels
normalized by week 16.
Safety of grazoprevir was evaluated in 87 treatment-naïve,
non-cirrhotic, genotype one patients by Lagging et al.22 Adverse
events were similar in all the three groups. One patient in this
study experienced myositis with transaminase levels >3× the
upper limit of normal (ULN), total bilirubin >2× ULN, and
CPK level of 1,032 U/L after 7 days of grazoprevir 100 mg.
The patient required discontinuation of therapy leading to
normalization of laboratory values.
The C-WORTHY study conducted by Sulkowski et al
reported common adverse events to be mild to moderate
fatigue, headache, nausea, and diarrhea.23 Overall, adverse
events occurred in 56% of the patients with three patients
reporting serious adverse events. Serious adverse events
consisted of one case of nausea, one of asthenia related to
the study drug, and one of staphylococcal infection, which
was determined to be unrelated to the study drug. Ribavirin
containing regimens had higher rates of adverse events,
bilirubin elevation, or hemoglobin decrease. Transaminase
elevations were not seen after 4 weeks of therapy.
Lawitz et al reported common adverse events of fatigue,
headache, and asthenia of mild to moderate intensity. 24
Serious adverse events were reported in seven patients, but
only one patient had abdominal pain which was thought to
be due to the study medication. One patient experienced
transaminase increase, which resolved without interruption
of therapy. Once again the rate of adverse events, bilirubin
elevation, and hemoglobin decrease was higher in groups
receiving ribavirin.
Most common adverse events reported in the C-WORTHY
part D study included headache, upper respiratory tract infection, and nausea.25 One patient discontinued therapy due to
experiencing dyspnea, fatigue, and asthenia 2–3 days after
starting treatment in the W18 group. C-EDGE-TN study also
reported common adverse events of headache, fatigue, and
nausea.26 There were nine serious adverse events reported,
none of which were attributed to the study drug. Two patients
discontinued study medication due to elevated aminotransferase levels and one patient due to palpitations and anxiety.
In the C-EDGE Co-Infection study, the most common side
effects were fatigue (13%), headache (12%), and nausea (9%)
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with no discontinuation due to adverse events.27 Two patients
had transient HIV viremia.
Both groups in the C-SALT study experienced common
adverse events of fatigue, arthralgia, nausea, and headache.19
Four serious adverse events were reported in the CP-B cirrhosis group, none of which were attributed to the study drug.
Transient bilirubin elevation without AST/ALT elevation was
noted in four patients and one patient died due to progression
of liver disease in the CP-B cirrhosis group.
In the C-EDGE CO-STAR study, occurrence of adverse
events reported was similar in both groups with most common adverse events being fatigue, headache, nausea, and
diarrhea.30 Serious adverse events were reported in 7% of the
ITG and 4% of the DTG. One death occurred in the DTG
group while on placebo.
Dusheiko et al conducted a safety analysis of grazoprevir/elbasvir from the results of studies published in which
the therapy was given for 8, 12, 16, or 18 weeks.36 Adverse
events and laboratory abnormalities reported on therapy or
within 14 days of end of treatment were evaluated. A total
of 1,795 patients were included in the evaluation: 1,033
received grazoprevir/elbasvir without ribavirin, 657 received
grazoprevir/elbasvir with ribavirin, and 105 received placebo.
Of the patients enrolled, 61% were male, 13% were Black,
27% had compensated cirrhosis, and 18% were HIV/HCV
co-infected. The safety profile of grazoprevir/elbasvir without
ribavirin was similar to placebo but the addition of ribavirin
was associated with more adverse events. The most commonly reported adverse events were headache and fatigue in
the patients receiving grazoprevir/elbasvir with or without
ribavirin. There were three deaths among patients receiving
grazoprevir/elbasvir that were unrelated to the study medication, while no patients in the placebo group died. Sex, age,
presence of cirrhosis, and HIV/HCV co-infection were not
associated with adverse events. ALT elevations of >5× the
ULN at or after treatment week 8 occurred in 0.8% of the
patients with normal ALT values at baseline. The ALT elevations were asymptomatic and the values normalized in the
majority of the cases without any intervention.

Resistance-associated substitution
Development of RAS occurs due to the combination of high
replication rate (1012 virions/day) of HCV and viral replication prone to errors. RAS testing is generally performed at
baseline and at the time of virologic failure. NS3 and NS5A
genes are amplified with a reverse transcription polymerase
chain reaction and population sequencing.28 Response to
suppression of these sequences is compared to wild-type
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HCV sequencing for reference and categorized as low- or
high-level resistance. Decreased efficacy of antiviral drugs is
attributed to the continuous production of the RAS. Known
variants associated with resistance to protease inhibitors
include Q41R, F43S, R155K, V36M, T54S/A, and D168.
Grazoprevir and elbasvir in vitro studies have shown no crossresistance among them as these agents are active against one
another’s RAS.37 Manns et al obtained baseline RAS in 261
of 264 patients.20 They identified 73 patients (28%) who had
the presence of RAS to at least one other protease inhibitor.
Of the 73 patients, 96% achieved SVR24 and six patients
experienced virologic treatment failure. Howe et al further
analyzed virologic resistance among the six patients.21 To
assess genotypic variation at baseline or at virologic failure,
the NS3/4A gene was amplified from samples with RNA
levels ≥1,000 IU/mL using reverse transcription polymerase
chain reaction followed by population and selective clonal
sequences. Resultant amino acid sequences were compared
to wild-type HCV1a or 1b reference sequences. A single
NS3A protease amino acid substitution was considered
clinically relevant. Five of the six patients with virologic
treatment failure were in the 100 mg/day group. Four of the
five patients were found to have low or undetectable trough
plasma levels compared to the median levels in the pharmacokinetic substudy. One patient who experienced virologic
treatment failure in the 200 mg/day group was infected with
genotype 1b at the initiation of treatment, but had reinfection
with genotype 3a after completion of treatment.
Sulkowski et al assessed the presence of RAS in patients
receiving grazoprevir/elbasvir treatment.23 Seventy-five
patients out of 216 (35%) had the presence of NS3 RAS at
baseline; 68 patients (91%) achieved SVR12. At baseline, 25
patients (12%) had the presence of NS5A RAS known to
have more than five-fold resistance to elbasvir or other NS5A
inhibitors. Seventeen of the 25 patients (68%) achieved SVR12.
Lawitz et al assessed the presence of RAS at baseline and
at treatment failure.24 At baseline, NS3 RAS were present in
79 of 248 patients (32%) and SVR12 was achieved in 73 of 79
patients (92%). NS5A RAS were present in 34 of 243 patients
(14%) at baseline, of whom 28 achieved SVR12 (82%). Ten
patients had virologic treatment failure. Eight of 10 patients
had detectable NS3 or NS5A RAS present. Common RAS
detected in these patients included NS3:Y56H, A156T/G/V,
D168A/Y, NS5A:M28T, Q30L/R, L31M, and Y93H/N.
Based on the results of these studies, cross-resistance of many
RAS, selected by other protease inhibitors, to grazoprevir/
elbasvir, seems to be absent. In patients with prior exposure to
protease inhibitors, C-SALVAGE demonstrated rare potential

for transient NS3 RAS as well as rare NS5A RAS persisting
over the 24-week follow-up.28 Due to concerns with RAS
leading to virologic failures, baseline polymorphism testing
should be done prior to initiation of grazoprevir/elbasvir and
duration of therapy should be adjusted accordingly.38
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Drug interactions
Both grazoprevir and elbasvir are substrates of CYP3A4 and
P-glycoprotein. Grazoprevir is also a substrate of the organic
anion-transporting polypeptide (OATP). Co-administration
of grazoprevir/elbasvir with OATP1B1/3 is contraindicated.
Use of strong inducers of CYP3A4 is contraindicated while
on grazoprevir/elbasvir, and use of moderate CYP3A4 inducers or inhibitors is not recommended while on grazoprevir/
elbasvir therapy. Grazoprevir/elbasvir use in combination
with statins should be used cautiously as exposure to statins
is increased. Drug-drug interactions with grazoprevir and
elbasvir are summarized in Tables 4 and 5.38

Conclusion
The grazoprevir/elbasvir regimen has significant advantages
over first-generation direct-acting agents. It has a favorable
pharmacokinetic profile with high liver concentration that
allows for once-daily dosing with a single tablet. Grazoprevir/elbasvir demonstrates a high barrier to resistance with
activity against substitutions known to have resistance to
first-generation protease inhibitors.37 It demonstrates high
SVR rates among HCV genotype 1 and 4 treatment-naïve
and treatment-experienced patients, including compensated
cirrhotics, without necessity of interferon injection. In addition, it presents an option for therapy without the need for
Table 4 Use of medications contraindicated with grazoprevir/
elbasvir38
Contraindicated medications that cause decreases in grazoprevir and
elbasvir plasma concentrations due to CYP3A induction, leading to loss
of virologic response:
• Phenytoin
• Carbamazepine
• Rifampin
• St. John’s Wort (Hypericum perforatum)
• Efavirenz
Contraindicated medications that cause significant increase in
grazoprevir plasma concentrations due to OATP1B1/3 inhibition which
may lead to ALT elevations:
• Atazanavir
• Darunavir
• Lopinavir
• Saquinavir
• Tipranavir
• Cyclosporine
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Table 5 Drug-drug interactions of grazoprevir and elbasvir
Medication

Effect on
concentration

Comment

Nafcillin

Decreases grazoprevir
and elbasvir
concentrations
Increases grazoprevir
and elbasvir
concentrations
Decreases grazoprevir
and elbasvir
concentrations
Decreases grazoprevir
and elbasvir
concentrations
Increases grazoprevir
and elbasvir
concentrations

Co-administration not
recommended

Ketoconazole

Bosentan

Etravirine

Elvitegravir/
cobicistat/
emtricitabine/
tenofovir
(disoproxil
fumarate or
alafenamide)
Modafinil

Tacrolimus

Atorvastatin

Decreases grazoprevir
and elbasvir
concentrations
Increased tacrolimus
concentrations

Increases
concentrations of
statins

Fluvastatin
Lovastatin
Simvastatin
Rosuvastatin

Frequent monitoring of
tacrolimus whole blood
concentrations, renal
function, and adverse
events upon initiation
of co-administration is
recommended
Do not exceed atorvastatin
20 mg daily dose while on
grazoprevir/elbasvir
Use lowest necessary statin
dose and monitor closely
for myopathy while on
grazoprevir/elbasvir
Do not exceed rosuvastatin
10 mg daily dose while on
grazoprevir/elbasvir

Note: Data from Zepatier™ (elbasvir/grazoprevir) [package insert].38

ribavirin in genotype 1 patients. Further data are needed
on the potential for use of this medication in patients with
decompensated cirrhosis.
Grazoprevir/elbasvir has also demonstrated efficacy
among HCV/HIV co-infected patients with SVR12 rates
greater than 95% in HCV genotype 1, 4, and 6 patients.27
These data suggest that the efficacy of grazoprevir/elbasvir
is similar in mono-infected and co-infected patients. Since
grazoprevir is a mild CYP3A4 inhibitor, there are clinically
important drug-drug interactions that should be thoroughly
evaluated when it is utilized concomitantly with anti-retroviral
therapy. Grazoprevir/elbasvir does not have an interaction with
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pantoprazole or famotidine, thus making this regimen more
attractive for patients who take these agents, as other HCV
DAA regimens require separation of acid reducing agents.
There has been an unmet medical need to treat HCV infection in patients with CKD and those on hemodialysis. Clinical
trials with grazoprevir/elbasvir in CKD demonstrate extremely
promising efficacy and tolerability.29 With an aging HCV
population and expected increased incidence of renal impairment in this cohort, the grazoprevir/elbasvir regimen seems
particularly attractive, representing the first oral ribavirin-free
regimen to be evaluated in this patient population.
Current data demonstrate the combination of grazoprevir/elbasvir to be a very efficacious regimen representing a
strong protease inhibitor/NS5A inhibitor oral, single-tablet
regimen for treatment of HCV infection in patients with
compensated cirrhosis, HCV/HIV co-infection and with
CKD. Additionally, it represents a medication that maintains
safety and efficacy regardless of the severity of fibrosis. A
high degree of all-oral efficacy was maintained even among
patients with prior exposure to earlier generation protease
inhibitors.28 This regimen is safe and effective and is well
tolerated among HCV patients with narcotic and opioid
dependence including methadone and cocaine.30 The robust
data among the general genotype 1 and 4 population provide
another option for a field in need of a viable competitive
market, for which cost of therapy is the limiting factor. These
data include patients with cirrhosis, treatment experience,
HIV co-infection, exposure to protease inhibitors and those
on dialysis – potentially expanding the utility of this regimen
in a broad arena of patients.
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